慢性淋巴细胞白血病转化-Richter综合征治疗进展  

Progress of novel therapy in the treatment of chronic lymphocytic leukemia transforming Richter syndrome

作　　者：张佼佼[1] 罗菁 糜坚青[1] ZHANG Jiaojiao;LUO Jing;MI Jianqing(Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai,200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院血液科,上海血液学研究所,国家医学基因重点实验室,国家转化医学研究中心,上海200025

出　　处：《临床血液学杂志》2024年第1期70-75,共6页Journal of Clinical Hematology

摘　　要：Richter综合征是一种在慢性淋巴细胞白血病/小细胞淋巴瘤(chronic lymphocytic leukemia/small lymphocytic lymphoma,CLL/SLL)基础上发展的侵袭性淋巴瘤。目前大部分转化患者预后极差,特别是与CLL/SLL存在克隆相关的转化患者对传统化学免疫治疗疗效不理想。通过联合应用新型靶向药物以及细胞免疫治疗等手段,在一定程度上可以改善这部分患者的疗效;同时也为年龄适合的患者创造了获得移植的机会。本文我们主要阐述了CLL/SLL转化为Richter综合征的治疗进展。Richter syndrome refers to an aggressive lymphoma that develops based on chronic lymphocytic leukemia/small lymphocytic lymphoma(CLL/SLL).The majority of transformed patients currently have an inferior prognosis,and in particular,conventional chemoimmunotherapy showed poor efficacy in clonal related patients.This group of patients may benefit from combinations of novel targeted agents and/or cellular immunotherapy.These new strategies also offer opportunities for patients who are age-appropriate for transplantation.In this review,we focus on current advances related to the therapeutic strategies available for this disease.

关 键 词：RICHTER综合征 靶向药物 免疫治疗 移植 治疗进展 

分 类 号：R733.4[医药卫生—肿瘤]